MDLN vs. VEEV: Medline vs. Veeva Systems Stock Comparison

Company Profile

Medline (MDLN) and Veeva Systems (VEEV) both fall under the Health Care Equipment & Services industry group, but MDLN is classified in Health Care Equipment & Supplies while VEEV is classified in Health Care Technology.

Veeva Systems (VEEV) has been public since October 16, 2013 with a meaningfully longer listed history, while Medline (MDLN) only listed on December 17, 2025 — long-window metrics on the MDLN side should be interpreted with caution.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Veeva Systems (VEEV) has a non-negative beta of 0.88.

Risk-Adjusted Performance

Risk-Return Positioning

Both MDLN and VEEV need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Veeva Systems (VEEV) at 14.43% sits in the top ROE quartile, while Medline (MDLN) at 4.85% is closer to the peer norm — stronger capital efficiency for VEEV.

Veeva Systems (VEEV) at 29.35% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

Veeva Systems (VEEV) at 29.64% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Veeva Systems (VEEV) reports revenue growth of 16.34%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than Veeva Systems (VEEV) at 25.93%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Both Medline (MDLN) at 4.04 and Veeva Systems (VEEV) at 5.46 post current ratio above their industries’ typical mid-ranges — short-term liquidity appears comfortable, though unusually high readings can point to idle current assets.

Veeva Systems (VEEV) at 0.02 keeps leverage in the lower industry quartile, while Medline (MDLN) at 0.65 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Medline (MDLN) nor Veeva Systems (VEEV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Medline (MDLN) nor Veeva Systems (VEEV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Veeva Systems (VEEV) at 49.79 sits in the richer P/E ratio quartile, and Medline (MDLN) at 90.09 is richer still, above its industry range.

Medline (MDLN) at 1.70 prices around its industry’s typical P/S ratio, while Veeva Systems (VEEV) at 14.22 clears its benchmark range — VEEV looks notably rich on sales.

Medline (MDLN) at 2.95 is valued about in line with its industry on P/B ratio, while Veeva Systems (VEEV) at 6.61 carries an above-peer premium to book — VEEV is pricier on assets.

Valuation Metrics